Dinutuximab (Unituxin) | Zendy

Reimbursement Team | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Dinutuximab (Unituxin)

Author(s) -

Reimbursement Team

Publication year - 2021

Publication title -

canadian journal of health technologies

Language(s) - English

Resource type - Journals

ISSN - 2563-6596

DOI - 10.51731/cjht.2021.125

Subject(s) - reimbursement , medicine , irinotecan , temozolomide , drug , refractory (planetary science) , intensive care medicine , family medicine , pharmacology , cancer , chemotherapy , health care , political science , physics , colorectal cancer , law , astrobiology

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.This review assesses dinutuximab (Unituxin) 17.5 mg/m2 per day, administered as an IV infusion over 10 hours to 20 hours for 4 consecutive days per treatment cycle.Indication: For the treatment of high-risk neuroblastoma patients in their first relapse or determination of refractory disease in combination with irinotecan, temozolomide, andgranulocyte-macrophage colony-stimulating factor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research